USPTO Examiner ALLEN MARIANNE P - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19033679ANTIBODIES TARGETING IL3January 2025May 2025Allow411NoNo
18988612SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATIONDecember 2024April 2025Allow410NoNo
18979795ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USEDecember 2024May 2025Allow511YesNo
18772062TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOFJuly 2024October 2024Allow310NoNo
18642478APPLICATION OF A NANOBODY TARGETING ON IL-6RAApril 2024January 2025Allow920NoNo
18593108ANTI-HUMAN INTERLEUKIN-33 MONOCLONAL ANTIBODY AND USE THEREOFMarch 2024March 2025Allow1220NoNo
18429738Method for Producing an Active Hepatocyte Growth Factor (HGF)February 2024May 2025Allow1610NoNo
18448054Heparin-Associated Polypeptides and Uses ThereofAugust 2023May 2024Abandon910NoNo
18339094ANTIGEN-BINDING MOLECULES AND USES THEREOFJune 2023April 2024Allow911NoNo
18322927HEAVY CHAIN ONLY ANTIBODIES TO PDGFMay 2023March 2025Abandon2210NoNo
18311771ANTI-CD28 X ANTI-PSMA ANTIBODIESMay 2023January 2024Allow910NoNo
18311082LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOFMay 2023October 2024Allow1821YesNo
18307729COMPOSITIONSApril 2023March 2025Abandon2310NoNo
18304598ANTI C-MET ANTIBODIESApril 2023May 2025Allow2511NoNo
18172987ANTI-CD28 X ANTI-PSMA ANTIBODIESFebruary 2023January 2025Allow2321NoNo
18165515EGFR x CD28 MULTISPECIFIC ANTIBODIESFebruary 2023May 2025Allow2700NoNo
18164351IL10 RECEPTOR BINDING MOLECULES AND METHODS OF USEFebruary 2023July 2024Allow1721NoNo
18018448IL12 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USEJanuary 2023December 2024Allow2341NoNo
18160355METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASEJanuary 2023November 2024Allow2210NoNo
18006831IL10RA BINDING MOLECULES AND METHODS OF USEJanuary 2023January 2025Allow2441YesNo
18017838IL10Ra/IL2Ry SYNTHETIC CYTOKINESJanuary 2023March 2025Allow2641NoNo
18017836IL2RB/IL2RG SYNTHETIC CYTOKINESJanuary 2023November 2024Abandon2231NoNo
18068977CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIESDecember 2022December 2024Abandon2410NoNo
18065504DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINESDecember 2022January 2024Abandon1301NoNo
18077137Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses ThereofDecember 2022June 2025Allow3020NoNo
18071057FULLY HUMANIZED ANTI-PLATELET FACTOR 4 ANTIBODIES THAT TREAT HEPARIN-INDUCED THROMBOCYTOPENIANovember 2022October 2024Allow2220NoNo
17990497METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022September 2024Abandon2201NoNo
17990515METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022October 2024Abandon2201NoNo
17990460METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022August 2024Abandon2101NoNo
17990492METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022August 2024Abandon2101NoNo
17990478METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022August 2024Abandon2101NoNo
17990507METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022October 2024Abandon2201NoNo
17990438METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022September 2024Abandon2201NoNo
17818798COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASEAugust 2022January 2024Abandon1710NoNo
17850135ANTI-ACTH ANTIBODIES AND USE THEREOFJune 2022March 2025Allow3211NoNo
17850339CYSTEINE LINKED NANOBODY DIMERSJune 2022April 2025Allow3421NoNo
17807939ARTHRITIS TREATMENTJune 2022June 2024Allow2410NoNo
17842904ANTI-ANGPT2 ANTIBODIESJune 2022May 2024Allow2310NoNo
17831398ANTI-CCR8 ANTIBODIES AND USES THEREOFJune 2022October 2024Allow2921NoNo
17777021TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOFMay 2022September 2024Abandon2801NoNo
17737343A Method for Producing An Active Hepatocyte Growth Factor (HGF)May 2022June 2024Abandon2510NoNo
17724639COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEApril 2022February 2023Abandon1011NoNo
17719496IMMUNOGLOBULIN VARIABLE DOMAINSApril 2022March 2023Allow1130NoNo
17702890MONOCLONAL ANTIBODIES TO ANGIOTENSIN-(1-12), COMPOSITIONS INCLUDING THE SAME, AND METHODS OF USE THEREOFMarch 2022March 2025Allow3631YesNo
17699925ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USEMarch 2022June 2024Abandon2720NoNo
17678861METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASEFebruary 2022November 2022Allow920NoNo
17592381Cancer Antigen PeptideFebruary 2022October 2023Abandon2001NoNo
17592375Cancer Antigen PeptideFebruary 2022September 2023Abandon1901NoNo
17592384Cancer Antigen PeptideFebruary 2022October 2023Abandon2001NoNo
17586620METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSISJanuary 2022November 2023Abandon2201NoNo
17583503HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORSJanuary 2022March 2024Allow2611NoNo
17579376Humanized Anti-VEGF Monoclonal AntibodyJanuary 2022March 2024Allow2620NoNo
17562499IMMUNOGLOBULIN VARIABLE DOMAINSDecember 2021June 2022Allow510NoNo
17559808ANTI-ANGPTL 3/8 COMPLEX ANTIBODIES AND METHODS OF USING THE SAMEDecember 2021August 2024Allow3220NoNo
17556193Modulation of Heparin-Binding Epidermal Growth Factor Activity for Tympanic Membrane HealingDecember 2021March 2024Allow6020NoNo
17539335METHODS OF TREATING FGF21-ASSOCIATED DISORDERSDecember 2021June 2023Allow1910NoNo
17528378RELAXIN FUSION POLYPEPTIDES AND USES THEREOFNovember 2021August 2023Allow2110NoNo
17453894TREATMENT OF PSYCHIATRIC CONDITIONSNovember 2021August 2023Abandon2110NoNo
17501430COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEOctober 2021July 2023Abandon2101NoNo
17450872COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEOctober 2021March 2024Abandon2921YesNo
17498262FUSION PROTEINS WITH EXTENDED SERUM HALF LIFEOctober 2021December 2023Allow2611YesNo
17481938COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIESSeptember 2021December 2023Abandon2711NoNo
17469044ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USESeptember 2021August 2023Allow2310NoNo
17466276ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USESeptember 2021May 2023Allow2001NoNo
17462795MONOSPECIFIC AND BISPECIFIC ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOFAugust 2021March 2024Allow3121NoNo
17412066NOVEL IGFR-LIKE 2 RECEPTOR AND USES THEREOFAugust 2021January 2024Allow2920YesNo
17407774FGFR3 ANTIBODIES AND METHODS OF USEAugust 2021August 2022Allow1221YesNo
17407012Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A AntagonistsAugust 2021May 2025Abandon4521NoYes
17397121HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOFAugust 2021May 2025Allow4621NoYes
17395800COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODSAugust 2021September 2024Allow3721NoNo
17381537EPCAM ANTIBODY AND EPCAM-CAR-T CELLSJuly 2021October 2024Allow3901NoNo
17379909Method for Treating a Cancer Based on Inflammatory Subtype ThereofJuly 2021November 2024Allow4021NoNo
17378557MODIFIED FIBROBLAST GROWTH FACTORS FOR THE TREATMENT OF OCULAR DISORDERSJuly 2021April 2024Abandon3321NoNo
17341325HEAVY CHAIN ONLY ANTIBODIES TO PDGFJune 2021June 2023Abandon2510NoNo
17335355Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and DisordersJune 2021October 2023Abandon2811NoNo
17240218FUSION POLYPEPTIDES AND METHODS OF USEApril 2021April 2025Allow4831NoNo
17235653COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORNEAL HAZE AND SCARRINGApril 2021May 2023Allow2510NoNo
17233083HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST ACTIVATION PROTEINApril 2021August 2024Allow4020NoNo
17230289ANTI-FLT3 ANTIBODIES AND COMPOSITIONSApril 2021November 2024Allow4331NoNo
17216273OXIDIZED CARDIOLIPIN AS A PRO-INFLAMMATORY FACTORMarch 2021April 2023Abandon2410NoNo
17215163IMMUNOGLOBULIN VARIABLE DOMAINSMarch 2021February 2022Allow1021NoNo
17215121IMMUNOGLOBULIN VARIABLE DOMAINSMarch 2021June 2022Allow1441NoNo
17215039IMMUNOGLOBULIN VARIABLE DOMAINSMarch 2021January 2022Allow1021NoNo
17208483HEPATOCYTE GROWTH FACTOR FRAGMENTS THAT FUNCTION AS POTENT MET RECEPTOR AGONISTS AND ANTAGONISTSMarch 2021July 2024Abandon3930NoNo
17208292TIE2-BINDING AGENTS AND METHODS OF USEMarch 2021July 2023Allow2811NoNo
17205663ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USEMarch 2021December 2022Allow2121YesNo
17205573ENDOGLIN POLYPEPTIDES AND USES THEREOFMarch 2021October 2023Abandon3111NoNo
17199810ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOFMarch 2021April 2023Allow2611NoNo
17191651METHODS FOR THE TREATMENT OF THYROID EYE DISEASEMarch 2021March 2022Abandon1320NoNo
17270987AFUCOSYLATED ANTIBODIES AND MANUFACTURE THEREOFFebruary 2021December 2024Abandon4511NoNo
17168055METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONSFebruary 2021February 2024Abandon3621NoNo
17163892ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITISFebruary 2021October 2024Abandon4421NoNo
17154366METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFJanuary 2021February 2023Abandon2510NoNo
17154340METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFJanuary 2021March 2023Abandon2610NoNo
17149570PROPHYLACTIC AGENT, ONSET-SUPPRESSING AGENT OR THERAPEUTIC AGENT FOR PROGRESSIVE IMMUNE DEMYELINATING DISEASESJanuary 2021August 2024Allow4330YesNo
17130152BIO-MIMETIC FORMULATIONDecember 2020March 2023Abandon2710NoNo
17255254ANTI-FLT-1 ANTIBODIES IN TREATING BRONCHOPULMONARY DYSPLASIADecember 2020July 2024Abandon4320NoNo
17127600FGF21 Mimetic Antibodies and Uses ThereofDecember 2020February 2023Allow2610NoNo
17253372AFFINITY CARRIER USING MUTANT VHH ANTIBODYDecember 2020September 2024Allow4520YesNo
17252525BI-AND TRI-FUNCTIONAL FUSION PROTEINS AND USES THEREOFDecember 2020April 2024Abandon4001NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEN, MARIANNE P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
17
Examiner Affirmed
16
(94.1%)
Examiner Reversed
1
(5.9%)
Reversal Percentile
20.5%
Lower than average

What This Means

With a 5.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
110
Allowed After Appeal Filing
12
(10.9%)
Not Allowed After Appeal Filing
98
(89.1%)
Filing Benefit Percentile
11.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 10.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ALLEN, MARIANNE P - Prosecution Strategy Guide

Executive Summary

Examiner ALLEN, MARIANNE P works in Art Unit 1647 and has examined 1,182 patent applications in our dataset. With an allowance rate of 52.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner ALLEN, MARIANNE P's allowance rate of 52.1% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALLEN, MARIANNE P receive 2.21 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALLEN, MARIANNE P is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +25.0% benefit to allowance rate for applications examined by ALLEN, MARIANNE P. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.6% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 49.9% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 80.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.4% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.1% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.4% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.